TWI712409B - 具有增進之治療指數的硝醯基予體 - Google Patents

具有增進之治療指數的硝醯基予體 Download PDF

Info

Publication number
TWI712409B
TWI712409B TW107143952A TW107143952A TWI712409B TW I712409 B TWI712409 B TW I712409B TW 107143952 A TW107143952 A TW 107143952A TW 107143952 A TW107143952 A TW 107143952A TW I712409 B TWI712409 B TW I712409B
Authority
TW
Taiwan
Prior art keywords
compound
formula
pharmaceutical composition
administered
compounds
Prior art date
Application number
TW107143952A
Other languages
English (en)
Chinese (zh)
Other versions
TW201934120A (zh
Inventor
傑可 卡利什文森
亞瑟 布魯克菲爾德費德列克
馬汀 考特尼史蒂芬
瑪莉 弗羅斯特麗莎
P 托斯卡諾約翰
Original Assignee
美商卡爾迪奧克斯爾製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商卡爾迪奧克斯爾製藥公司 filed Critical 美商卡爾迪奧克斯爾製藥公司
Publication of TW201934120A publication Critical patent/TW201934120A/zh
Application granted granted Critical
Publication of TWI712409B publication Critical patent/TWI712409B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW107143952A 2013-01-18 2014-01-17 具有增進之治療指數的硝醯基予體 TWI712409B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US61/754,237 2013-01-18
US201361782781P 2013-03-14 2013-03-14
US61/782,781 2013-03-14

Publications (2)

Publication Number Publication Date
TW201934120A TW201934120A (zh) 2019-09-01
TWI712409B true TWI712409B (zh) 2020-12-11

Family

ID=50064795

Family Applications (3)

Application Number Title Priority Date Filing Date
TW107143952A TWI712409B (zh) 2013-01-18 2014-01-17 具有增進之治療指數的硝醯基予體
TW103101912A TWI619491B (zh) 2013-01-18 2014-01-17 包含硝醯基予體的醫藥組合物
TW103101913A TWI686193B (zh) 2013-01-18 2014-01-17 具有增進之治療指數的硝醯基予體

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW103101912A TWI619491B (zh) 2013-01-18 2014-01-17 包含硝醯基予體的醫藥組合物
TW103101913A TWI686193B (zh) 2013-01-18 2014-01-17 具有增進之治療指數的硝醯基予體

Country Status (29)

Country Link
US (13) US8987326B2 (enExample)
EP (5) EP3284463B1 (enExample)
JP (5) JP6533159B2 (enExample)
KR (2) KR102177899B1 (enExample)
CN (4) CN110179777B (enExample)
AU (5) AU2014207404B2 (enExample)
BR (2) BR112015017251B1 (enExample)
CA (2) CA2898445C (enExample)
CY (3) CY1120535T1 (enExample)
DK (3) DK3284463T3 (enExample)
ES (4) ES2659969T3 (enExample)
HK (1) HK1251170B (enExample)
HR (3) HRP20180121T1 (enExample)
HU (3) HUE036589T2 (enExample)
IL (4) IL239906B (enExample)
LT (3) LT3284463T (enExample)
MX (2) MX363843B (enExample)
NZ (4) NZ709986A (enExample)
PL (3) PL2945621T3 (enExample)
PT (3) PT2945620T (enExample)
RS (3) RS59434B1 (enExample)
RU (3) RU2684916C2 (enExample)
SG (6) SG11201505568PA (enExample)
SI (3) SI2945620T1 (enExample)
SM (3) SMT201900575T1 (enExample)
TR (1) TR201802211T4 (enExample)
TW (3) TWI712409B (enExample)
WO (2) WO2014113696A1 (enExample)
ZA (2) ZA201505090B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029309T2 (en) 2006-03-17 2017-02-28 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as novel physiologically useful nitroxyl donors
CA2852914C (en) 2011-10-17 2019-11-26 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
BR112015017251B1 (pt) 2013-01-18 2021-10-26 Cardioxyl Pharmaceuticals, Inc. Composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
ES2749682T3 (es) 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
CN108349911B (zh) 2015-09-07 2022-05-13 浙江华海药业股份有限公司 可释放一氧化氮的前药分子
JP6889704B2 (ja) 2015-10-19 2021-06-18 カルディオキシル ファーマシューティカルズ，インク． ニトロキシルドナーとしてのピラゾロン誘導体
EP3365325A1 (en) 2015-10-19 2018-08-29 Cardioxyl Pharmaceuticals Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
KR20190070912A (ko) 2016-07-28 2019-06-21 더 존스 홉킨스 유니버시티 O-치환된 히드록삼산
AU2018205621B2 (en) * 2017-01-03 2023-01-05 Cardioxyl Pharmaceuticals, Inc. Method of administering nitroxyl donating compounds
CN110536683A (zh) * 2017-04-18 2019-12-03 基恩菲特公司 包含PPAR激动剂如伊拉非诺和乙酰CoA羧化酶ACC抑制剂的组合
CN116283762B (zh) * 2023-03-28 2025-08-12 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
ATE66143T1 (de) 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
CN1143950A (zh) * 1994-01-19 1997-02-26 比克荷兰有限公司 含硝酰基的苄胺衍生物及其在治疗心血管疾病和治疗升高眼压中的应用
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
CA2306914A1 (en) 1997-10-24 1999-05-06 Shionogi & Co., Ltd. Antirheumatic
ATE236136T1 (de) * 1998-01-16 2003-04-15 Hoffmann La Roche Benzosulfonderivate
US6295153B1 (en) 1998-06-04 2001-09-25 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
AU4800999A (en) 1998-07-28 2000-02-21 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
ES2267853T3 (es) 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
US20090281067A1 (en) 2004-01-30 2009-11-12 The John Hopkins University Nitroxyl progenitor compounds and methods of use
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008543947A (ja) 2005-06-23 2008-12-04 ジョンズ ホプキンス ユニバーシティ チオール感受性の正の変力物質
HUE029309T2 (en) 2006-03-17 2017-02-28 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as novel physiologically useful nitroxyl donors
EP2010476A4 (en) 2006-04-13 2011-01-26 Univ Wake Forest Health Sciences NITROXYL DISPENSERS FROM C-NITROSO COMPOUNDS
MX2010003232A (es) 2007-09-26 2010-08-23 Univ Johns Hopkins Derivados de n-hidroxisulfonamida como nuevos donadores de nitroxilo fisiologicamente utiles.
HUE030372T2 (en) * 2008-05-07 2017-05-29 Cardioxyl Pharmaceuticals Inc New nitroso compounds as nitroxyl donors and methods for their use
WO2011063339A1 (en) 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
WO2011071951A2 (en) 2009-12-07 2011-06-16 Johns Hopkins University N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
JP5832447B2 (ja) 2009-12-07 2015-12-16 ザ ジョンズ ホプキンス ユニバーシティ ビスアシル化ヒドロキシルアミン誘導体
CA2852914C (en) 2011-10-17 2019-11-26 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
EP2914579A1 (en) 2012-11-01 2015-09-09 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
BR112015017251B1 (pt) 2013-01-18 2021-10-26 Cardioxyl Pharmaceuticals, Inc. Composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
HRP20191919T1 (hr) 2020-01-10
SG10201913286PA (en) 2020-02-27
IL239906A0 (en) 2015-08-31
CY1122177T1 (el) 2020-11-25
SI2945620T1 (en) 2018-01-31
PL2945620T3 (pl) 2018-03-30
US20140206769A1 (en) 2014-07-24
TWI686193B (zh) 2020-03-01
TR201802211T4 (tr) 2018-03-21
EP3284463A1 (en) 2018-02-21
CA2898443A1 (en) 2014-07-24
AU2014207408C1 (en) 2018-09-06
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
MX373176B (es) 2020-04-22
EP3427728B1 (en) 2021-07-07
AU2018203240B2 (en) 2019-12-12
RS59434B1 (sr) 2019-11-29
NZ709986A (en) 2020-01-31
US20150175566A1 (en) 2015-06-25
ES2659969T3 (es) 2018-03-20
HUE041861T2 (hu) 2019-06-28
DK2945621T3 (en) 2019-02-11
US20220193026A1 (en) 2022-06-23
LT3284463T (lt) 2019-11-11
US9586896B2 (en) 2017-03-07
DK2945620T3 (en) 2018-02-05
CA2898445A1 (en) 2014-07-24
SMT201800088T1 (it) 2018-03-08
US20190133990A1 (en) 2019-05-09
DK3284463T3 (da) 2019-10-28
LT2945620T (lt) 2018-02-12
BR112015017241A8 (pt) 2019-10-29
RU2015134581A (ru) 2017-02-27
US11304924B2 (en) 2022-04-19
US11786501B2 (en) 2023-10-17
NZ748769A (en) 2020-05-29
ES2705240T3 (es) 2019-03-22
AU2014207408A8 (en) 2015-08-27
CA2898445C (en) 2022-05-03
ZA201604798B (en) 2018-01-31
PT2945620T (pt) 2018-02-21
US10245249B2 (en) 2019-04-02
HUE036589T2 (hu) 2018-07-30
JP2017125015A (ja) 2017-07-20
HK1216857A1 (en) 2016-12-09
AU2018241168B2 (en) 2020-04-02
US20240066002A1 (en) 2024-02-29
CA2898443C (en) 2022-05-31
TW201442702A (zh) 2014-11-16
RU2676277C2 (ru) 2018-12-27
IL239952A0 (en) 2015-08-31
IL259233A (en) 2018-07-31
RU2684916C2 (ru) 2019-04-16
JP6311038B2 (ja) 2018-04-11
NZ748771A (en) 2019-12-20
BR112015017241B1 (pt) 2021-10-26
US20210015784A1 (en) 2021-01-21
EP2945620B1 (en) 2017-11-22
WO2014113696A1 (en) 2014-07-24
HRP20182144T1 (hr) 2019-03-08
US20200163929A1 (en) 2020-05-28
RS58174B1 (sr) 2019-03-29
AU2017200147A1 (en) 2017-02-02
EP3567031A1 (en) 2019-11-13
HUE046722T2 (hu) 2020-03-30
MX363843B (es) 2019-04-05
US12186301B2 (en) 2025-01-07
BR112015017241A2 (pt) 2017-07-11
BR112015017251A2 (pt) 2017-07-11
CN110179777A (zh) 2019-08-30
US10548872B2 (en) 2020-02-04
BR112015017251A8 (pt) 2019-10-29
CN110179777B (zh) 2022-07-15
SI2945621T1 (sl) 2019-01-31
KR20150108879A (ko) 2015-09-30
JP2019172682A (ja) 2019-10-10
US8987326B2 (en) 2015-03-24
US10213408B2 (en) 2019-02-26
US20170151210A1 (en) 2017-06-01
JP2016510326A (ja) 2016-04-07
JP6533159B2 (ja) 2019-06-19
KR20150107853A (ko) 2015-09-23
ZA201505090B (en) 2016-10-26
JP6801045B2 (ja) 2020-12-16
MX2015009269A (es) 2015-10-30
IL239952B (en) 2018-05-31
NZ709985A (en) 2020-05-29
IL258882A (en) 2018-06-28
CN105073105A (zh) 2015-11-18
SG11201505567RA (en) 2015-09-29
SMT201900027T1 (it) 2019-02-28
CN108610312A (zh) 2018-10-02
US9156804B2 (en) 2015-10-13
SG10201802862WA (en) 2018-05-30
SG10201802855TA (en) 2018-05-30
IL239906B (en) 2018-05-31
TW201934120A (zh) 2019-09-01
CN105073105B (zh) 2018-02-27
US20180235927A1 (en) 2018-08-23
IL259233B (en) 2019-10-31
HK1216858A1 (en) 2016-12-09
ES2751922T3 (es) 2020-04-02
AU2018241168A1 (en) 2018-11-01
JP6656345B2 (ja) 2020-03-04
CY1121480T1 (el) 2020-05-29
EP2945620A1 (en) 2015-11-25
HRP20191919T8 (hr) 2021-10-01
JP2019089764A (ja) 2019-06-13
AU2014207408A1 (en) 2015-08-13
PT3284463T (pt) 2019-10-30
BR112015017251B1 (pt) 2021-10-26
CN105142627B (zh) 2019-06-21
US11273143B2 (en) 2022-03-15
TWI619491B (zh) 2018-04-01
LT2945621T (lt) 2019-01-10
RU2015134583A (ru) 2017-02-22
ES2882279T3 (es) 2021-12-01
AU2017200147B2 (en) 2018-07-05
KR102177899B1 (ko) 2020-11-12
MX2015009276A (es) 2015-10-30
EP3427728A1 (en) 2019-01-16
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
US20190224159A1 (en) 2019-07-25
PT2945621T (pt) 2019-01-21
CN105142627A (zh) 2015-12-09
AU2014207408B2 (en) 2018-03-01
AU2018203240A1 (en) 2018-05-31
PL2945621T3 (pl) 2019-05-31
PL3284463T3 (pl) 2019-12-31
AU2014207404B2 (en) 2017-10-19
SG10201913441RA (en) 2020-03-30
JP6449171B2 (ja) 2019-01-09
US10517847B2 (en) 2019-12-31
SMT201900575T1 (it) 2019-11-13
RU2018143994A (ru) 2019-01-16
HK1251170B (en) 2020-04-09
CY1120535T1 (el) 2019-07-10
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
EP3284463B1 (en) 2019-07-24
US10792273B2 (en) 2020-10-06
WO2014113700A1 (en) 2014-07-24
US9968584B2 (en) 2018-05-15
JP2016505044A (ja) 2016-02-18
TW201446242A (zh) 2014-12-16
AU2014207404A1 (en) 2015-08-13
HRP20180121T1 (hr) 2018-02-23
SI3284463T1 (sl) 2019-12-31
WO2014113700A9 (en) 2014-10-09
KR102277165B1 (ko) 2021-07-14

Similar Documents

Publication Publication Date Title
TWI686193B (zh) 具有增進之治療指數的硝醯基予體
HK40017499A (en) Nitroxyl donors with improved therapeutic index

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees